A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, anti-CD3 Monoclonal Antibody, in Children and Adolescents with Newly Diagnosed Type 1 Diabetes (T1D)

This Study is
No Longer Enrolling

Details
Age

Child

Type of Study

Treatment

Locations

Barbara Davis Center
Outpatient CTRC
UCD Barbara Davis Center
University of Colorado Hospital

Study ID

Protocol Number: 19-0489

More information available at ClinicalTrials.gov: NCT03875729

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers